At MDRNA we are focused on realizing the potential of RNAi-based therapeutics through the development of a broad-based, state-of-the-art drug discovery platform built upon industry leading expertise in RNA chemistry and oligonucleotide delivery. We bring optimal value to our partners, shareholders and ultimately to patients through the discovery and development of RNAi-based therapeutics against human diseases including critical unmet medical needs in areas such as oncology, inflammation and metabolic disorders.

25 September 2008: MDRNA, Inc. Receives NASDAQ Notice Letter

23 September 2008: MDRNA, Inc. to Present at the Maxim Group Growth Conference